Aspira Pathlab & Diagnostics Ltd.
Snapshot View

View in App

Prices View details

36.20 ▼0%

15 July 2021, 04:00:00 P.M.

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Hospital & Healthcare Services Compare with Industry peers
Website http://www.aspiradiagnostics.com
Financial Indicators
Market Cap 37.26 Cr.
Earnings per share (EPS) 1.34 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 27.00 Trailing Twelve Months Ending 2021-03
Industry PE 225.80 Trailing Twelve Months Ending 2021-03
Book Value / Share 7.95 Trailing Twelve Months Ending 2021-03
Price to Book Value 4.55 Calculated using Price: 36.20
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 1.03 Cr. 10,293,000 Shares
FaceValue 10
Company Profile
No Company Profile found.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
1 Week
1 Month
+21.07%
3 Month
+21.07%
6 Month
+35.33%
1 Year
+72.38%
2 Year
+4.02%
5 Year

Ratios View Details

9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 0.83 3.23 2.55 1.10 0.76 -57.04 -178.61 -187.57 -94.32
Return on Capital Employed (%) 1.36 4.99 3.88 3.95 1.78 -25.35 -38.38 -34.50 -26.30
Return on Assets (%) 0.77 3.22 2.55 1.05 0.54 -25.76 -40.76 -37.93 -29.11

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 1 1 1 4 4 6 0 5 4
Non Curr. Liab. 3 11 5 5
Curr. Liab. 0 3 6 2 4 5
Minority Int.
Equity & Liab. 1 1 1 4 6 15 13 15 14
Non Curr. Assets 1 11 11 13 11
Curr. Assets 1 1 1 4 6 4 2 2 3
Misc. Exp. not W/O
Total Assets 1 1 1 4 6 15 13 15 14

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 1 4 8 8
Other Income 0 0 0 0 0 0 0 0 0
Total Income 0 0 0 0 0 1 5 8 9
Total Expenditure 0 0 0 0 0 -3 -8 -11 -10
PBIDT 0 0 0 0 0 -2 -4 -3 -2
Interest 0 0 0 -1 -1 -1
Depreciation 0 -1 -1 -2
Taxation 0 0 0 0 0
Exceptional Items
PAT 0 0 0 0 -3 -6 -5 -4

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 0 0 0 0 -1 -5 -3 -2
Cash Fr. Inv. 0 0 0 0 0 -10 -1 -2 0
Cash Fr. Finan. 0 3 3 9 7 3 1
Net Change 0 0 3 2 -3 1 -2 0
Cash & Cash Eqvt 0 0 3 5 3 0 -2 -2

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 45.54 45.54 40.15 40.15 40.15 40.15 40.15 36.25 36.25
Public 54.46 54.46 59.85 59.85 59.85 59.85 59.85 63.75 63.75
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Tue, 13 Jul 2021
Shareholding for the Period Ended June 30 2021
Aspira Pathlab & Diagnostics Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Fri, 09 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Pursuant to Regulation 74 (5) of the SEBI (Depositories and Participants) Regulations 2018 we hereby submit a copy of certificate received from Link Intime (India) Private Limited Registrar and Share Transfer Agent of the Company certifying that for the quarter ended June 30 2021.
Fri, 02 Jul 2021
Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligation & Disclosure Requirements) Regulations 2015 For The Half Year Ended March 31 2021.<BR> <BR>
Pursuant to Regulation 23(9) of Securities and Exchange Board of India (Listing Obligation & Disclosure Requirements) Regulations 2015 we hereby submit the disclosure on Related Party Transactions on standalone basis drawn in accordance with applicable accounting standards for the half-year ended March 31 2021.

Technical Scans View Details

Thu, 15 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Stock Outperforming Sectoral Index in both 1 Week and 3 Month Stock Outperforming Sectoral Index in both 1 Week and 3 Month
Strongly Outperforming Benchmark Index Strongly Outperforming Benchmark Index
Increasing Relative Strength - Benchmark index Increasing Relative Strength - Benchmark index
Close Within 2 Year High Zone Close Within 2 Year High Zone

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,769.22 703.40 +1.4%
Divi's Laboratories Ltd. 130,349.05 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. 90,021.63 5,411.25 -0.2%
Cipla Ltd. 76,675.40 950.55 +0.3%
Cadila Healthcare Ltd. 61,992.73 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. 58,965.37 4,100.95 +4.7%
Aurobindo Pharma Ltd. 55,837.02 952.95 -1.1%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.12 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 65.69 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.13 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 31.88 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 29.06 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 392.16 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.47 952.95 -1.1%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 14.02 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.14 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 4.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.77 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.83 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.55 952.95 -1.1%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 0.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 952.95 -1.1%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 10.09 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 952.95 -1.1%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 12.53 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 952.95 -1.1%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 952.95 -1.1%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 952.95 -1.1%